Anti-Alzheimer's drug lecanemab
Haruo Naito, CEO of Japanese pharmaceutical company Eisai Co., attends a press conference in Tokyo on Dec. 13, 2023, as the company's anti-Alzheimer's drug lecanemab is set to be launched on Dec. 20, following a health ministry advisory body's approval of its coverage by the Japanese public insurance scheme.
- Product Code
- ILEA002090398
- Registered date
- 2023/12/13 00:00:00
- Credit
- Kyodo / Kyodo News Images
- Media source
- 2023 Kyodo News
- Media size
- 3918 × 2806 pixel
- Deployment size
- 532.56(KB)*
*File size when opened in Photoshop, etc.